menu
    • menu

    Company profile for Leap Therapeutics

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Leap has entered into a strategic collaboration with BeiGene, Ltd. for the rights to develop DKN-01 in ...
    Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Leap has entered into a strategic collaboration with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand. FL-301, is a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Leap TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    47 Thorndike St, Suite B1-1 Cambridge, MA 02141
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.leaptx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/leap-therapeutics
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Leap Jumps From Bio To Crypto After Winding Down Cancer Program
    Leap Jumps From Bio To Crypto After Winding Down Cancer Program

    12 Nov 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/leap-therapeutics-jumps-bio-crypto-after-winding-down-cancer-program

    FIERCE BIOTECH
    12 Nov 2025
    Share Share
    Leap Therapeutics Unveils Defiance Study Final Results at ESMO
    Leap Therapeutics Unveils Defiance Study Final Results at ESMO

    20 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/leap-therapeutics-presents-final-data-from-defiance-study-at-esmo-2025-302586914.html

    PR NEWSWIRE
    20 Oct 2025
    Share Share
    Leap Therapeutics Secures $58.88M Investment For Digital Asset
    Leap Therapeutics Secures $58.88M Investment For Digital Asset

    06 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/leap-therapeutics-announces-58-88-million-private-placement-in-cash-commitments-led-by-winklevoss-capital-to-initiate-a-digital-asset-treasury-strategy-302575729.html

    PR NEWSWIRE
    06 Oct 2025
    Share Share
    Leap Therapeutics To Present Defiance Study Part B Data At ESMO
    Leap Therapeutics To Present Defiance Study Part B Data At ESMO

    25 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/leap-therapeutics-to-present-final-clinical-data-from-part-b-of-the-defiance-study-at-the-esmo-congress-2025-302566702.html

    PR NEWSWIRE
    25 Sep 2025
    Share Share
    Leap Therapeutics Reports Second Quarter 2025 Financial Results
    Leap Therapeutics Reports Second Quarter 2025 Financial Results

    14 Aug 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/leap-therapeutics-reports-second-quarter-2025-financial-results-302529578.html

    PR NEWSWIRE
    14 Aug 2025
    Share Share
    Leap halves head count amid 'difficult market environment'
    Leap halves head count amid 'difficult market environment'

    13 May 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/leap-halves-headcount-narrows-lead-cancer-drugs-focus-amid-difficult-environment

    FIERCE BIOTECH
    13 May 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search